Department Of Biochemistry And Microbial Sciences

Permanent URI for this communityhttps://kr.cup.edu.in/handle/32116/23

Browse

Subject: search.filters.subject.Signaling pathways

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Current therapeutic modalities and chemopreventive role of natural products in liver cancer: Progress and promise
    (Baishideng Publishing Group Inc, 2023-01-15T00:00:00) Singh, Amit Kumar; Singh, Shiv Vardan; Kumar, Ramesh; Kumar, Shashank; Senapati, Sabyasachi; Pandey, Abhay K
    Liver cancer is a severe concern for public health officials since the clinical cases are increasing each year, with an estimated 5-year survival rate of 30%�35% after diagnosis. Hepatocellular carcinoma (HCC) constitutes a significant subtype of liver cancer (approximate75%) and is considered primary liver cancer. Treatment for liver cancer mainly depends on the stage of its progression, where surgery including, hepatectomy and liver transplantation, and ablation and radiotherapy are the prime choice. For advanced liver cancer, various drugs and immunotherapy are used as first-line treatment, whereas second-line treatment includes chemotherapeutic drugs from natural and synthetic origins. Sorafenib and lenvatinib are first-line therapies, while regorafenib and ramucirumab are secondline therapy. Various metabolic and signaling pathways such as Notch, JAK/ STAT, Hippo, TGF-?, and Wnt have played a critical role during HCC progression. Dysbiosis has also been implicated in liver cancer. Drug-induced toxicity is a key obstacle in the treatment of liver cancer, necessitating the development of effective and safe medications, with natural compounds such as resveratrol, curcumin, diallyl sulfide, and others emerging as promising anticancer agents. This review highlights the current status of liver cancer research, signaling pathways, therapeutic targets, current treatment strategies and the chemopreventive role of various natural products in managing liver cancer � The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved
  • No Thumbnail Available
    Item
    Obesity and Cancer
    (Springer Singapore, 2021-07-18T00:00:00) Kumar, Shashank; Gupta, Sanjay
    This book highlights the concordance between signaling pathways that are involved in obesity and cancer cross-talks. It describes the role of cytokines, chemokines, growth factors, insulin, and adipokines in the development of obesity-associated cancers. The book reviews the role of inflammatory signaling pathways such as estrogen-mediated signaling, mTOR and AMP-activated protein kinase pathway and the involvement of adaptive and innate immunity, oxidative stress, gene polymorphism, dietary phytochemicals, and miRNAs in obesity and cancer. In addition, it covers the latest research on the drugs and natural therapeutic agents that target obesity-induced cancers and discusses various in vivo models for studying obesity and obesity-associated cancer. Lastly, it analyses the role of genetic polymorphisms in the obesity-related genes that influence cancer development. The book is a useful resource for researchers in the field of cancer, pharmacology, food chemistry, and clinical biochemistry. � The Editor(s) (if applicable) and The Author(s), under exclusive license to Taylor and Francis Pte Ltd. 2021.